(The Hill) — Drugmaker AstraZeneca will cap out-of-pocket costs at $35 for all its inhaler products, the company announced Monday. The cap is effective June 1 and will apply to the company’s ...

Pharmaceutical giant GlaxoSmithKline is sidestepping its pledge to lower asthma inhaler prices, a key senator charged Wednesday, in the latest effort by Democrats to pressure drug companies on the ...

AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma.

The first-in class medicine for severe asthma co-developed by AstraZeneca and Amgen is poised for accelerated approval after the US Food and Drug Administration granted it a breakthrough designation.

Asthma is advancing relentlessly across the African continent. Today, 70% of African asthma and COPD sufferers are undiagnosed and the WHO forecasts a 20% increase in respiratory related deaths in the ...

Weather conditions in the United Arab Emirates (UAE) trigger asthma. While most adults are given medication to deal with such ailments, children often need emergency nebulisation treatments that are ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. The injectable drug will serve as an official partner of the Professional ...

AstraZeneca bought Belgian biotech company EsoBiotec in a deal valued at up to $1 billion, to expand its cell-therapy portfolio. The British pharma company said Monday that it will pay $425 ...